ATEA PHARMACEUTICALS INC's ticker is AVIR and the CUSIP is 04683R106. A total of 146 filers reported holding ATEA PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.87 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,357,651 | -39.1% | 6,452,550 | -24.1% | 0.00% | -33.3% |
| Q2 2023 | $31,779,924 | -59.0% | 8,497,306 | -63.3% | 0.00% | -25.0% |
| Q1 2023 | $77,541,640 | +37.3% | 23,146,758 | +97.2% | 0.00% | -33.3% |
| Q4 2022 | $56,456,937 | -20.6% | 11,737,409 | -6.0% | 0.01% | -14.3% |
| Q3 2022 | $71,061,000 | -20.2% | 12,488,746 | -0.4% | 0.01% | -22.2% |
| Q2 2022 | $89,030,000 | -2.0% | 12,539,475 | -0.3% | 0.01% | +28.6% |
| Q1 2022 | $90,826,000 | -18.5% | 12,579,791 | +0.9% | 0.01% | -12.5% |
| Q4 2021 | $111,441,000 | -74.4% | 12,465,409 | +0.4% | 0.01% | -77.1% |
| Q3 2021 | $435,324,000 | +63.3% | 12,416,533 | +0.0% | 0.04% | +66.7% |
| Q2 2021 | $266,579,000 | -59.9% | 12,410,530 | +15.4% | 0.02% | -63.2% |
| Q1 2021 | $664,357,000 | +146.6% | 10,758,795 | +66.9% | 0.06% | +137.5% |
| Q4 2020 | $269,384,000 | – | 6,447,692 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ABG Innovation Capital Partners III GP Ltd | 1,265,631 | $27,186,000 | 91.01% |
| Yu Fan | 143,867 | $3,090,000 | 34.92% |
| AJU IB Investment Co., Ltd. | 1,745,331 | $37,490,000 | 21.62% |
| Bain Capital Life Sciences Investors, LLC | 5,615,659 | $120,624,000 | 7.90% |
| Cormorant Asset Management, LP | 6,411,355 | $137,716,000 | 4.68% |
| Ally Bridge Group (NY) LLC | 373,288 | $8,018,000 | 1.99% |
| RA Capital Management | 5,368,451 | $115,314,000 | 1.85% |
| Omega Fund Management, LLC | 746,868 | $16,043,000 | 1.82% |
| CM Management, LLC | 90,000 | $1,933,000 | 1.40% |
| SECTORAL ASSET MANAGEMENT INC | 538,884 | $11,575,000 | 0.94% |